Baseline characteristics in 18 646 patients with type 2 diabetes, aged 30–80 years
| Aspirin | No aspirin | p Value* | p Value** | |
|---|---|---|---|---|
| Numbers | 4608 | 14038 | ||
| Age (years) | 65.2±8.3 | 61.4±9.8 | <0.001 | 0.85 |
| Diabetes duration (years) | 8.1±6.5 | 6.6±6.0 | <0.001 | 0.11 |
| HbA1c, % (mmol/mol) | 7.1±1.1 (54) | 7.0±1.2 (53) | 0.03 | 0.035 |
| Systolic BP (mm Hg) | 142±16 | 139±16 | <0.001 | 0.41 |
| BMI (kg/m2) | 29.8±5.0 | 29.6±5.3 | 0.02 | 0.68 |
| Total cholesterol (mmol/l) | 4.80±0.92 | 5.06±0.97 | <0.001 | – |
| HDL cholesterol (mmol/l) | 1.36±0.40 | 1.38±0.41 | 0.003 | – |
| Ratio total:HDL cholesterol | 3.77±1.16 | 3.93±1.27 | <0.001 | 0.07 |
| Male gender | 56.1 | 55.0 | 0.2 | 0.005 |
| Smoking | 15.0 | 15.5 | 0.3 | 0.60 |
| Albuminuria >20 µg/min | 24.2 | 18.5 | <0.001 | 0.90 |
| Previous hospitalisation | 4.5 | 4.4 | 0.8 | 0.68 |
| Hypoglycaemic treatment | ||||
| Oral agents only | 46.2 | 44.5 | 0.004 | 0.51 |
| Oral agents and insulin | 20.1 | 12.3 | <0.001 | 0.72 |
| Insulin only | 12.6 | 14.0 | 0.02 | 0.44 |
| ACE inhibitors | 32.8 | 18.8 | <0.001 | 0.70 |
| ACE inhibitors+diuretics | 5.3 | 2.6 | <0.001 | 0.56 |
| ACE inhibitors+Ca antagonists | 0.04 | 0.02 | 0.4 | 0.04 |
| AT2 antagonists | 15.2 | 9.9 | <0.001 | 0.91 |
| AT2 antagonists+diuretics | 9.8 | 5.2 | <0.001 | 0.40 |
| Ca antagonists | 26.3 | 14.2 | <0.001 | 0.23 |
| β Receptor blockers | 38.3 | 21.7 | <0.001 | 0.29 |
| Diuretics | 26.6 | 15.0 | <0.001 | 0.35 |
| α Receptor blockers | 1.5 | 0.7 | <0.001 | 0.68 |
| Statins | 55.7 | 29.1 | <0.001 | 0.19 |
| Other lipid lowering drugs | 2.5 | 1.6 | <0.001 | 0.39 |
| Oestrogen | 5.2 | 5.4 | 0.6 | 0.42 |
| Multidose dispensation | 1.1 | 0.8 | 0.07 | 0.35 |
Means±SD and frequencies (%) are given.
*Significance using t test or χ2 test.
**Significance using GLM after adjustment by stratification with a propensity score.
BMI, body mass index; BP, blood pressure; GLM, general linear modelling; HDL, high-density lipoprotein.